Literature DB >> 28627940

Delivery of drugs, growth factors, genes and stem cells via intrapericardial, epicardial and intramyocardial routes for sustained local targeted therapy of myocardial disease.

M G Katz1, A S Fargnoli1, R J Hajjar1, C R Bridges1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28627940      PMCID： PMC5881376          DOI： 10.1080/17425247.2017.1342405

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN： 1742-5247            Impact factor:   6.648


× No keyword cloud information.
  9 in total

1.  Incomplete retention after direct myocardial injection.

Authors:  P Michael Grossman; Zhenguo Han; Maria Palasis; James J Barry; Robert J Lederman
Journal:  Catheter Cardiovasc Interv       Date:  2002-03       Impact factor: 2.692

Review 2.  Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery.

Authors:  J Dobson
Journal:  Gene Ther       Date:  2006-02       Impact factor: 5.250

Review 3.  Delivery of drugs, growth factors, genes and stem cells via intrapericardial, epicardial and intramyocardial routes for sustained local targeted therapy of myocardial disease.

Authors:  Mikhail Maslov; Stephan Foianini; Mark Lovich
Journal:  Expert Opin Drug Deliv       Date:  2017-02-22       Impact factor: 6.648

Review 4.  Myocardial gene transfer: routes and devices for regulation of transgene expression by modulation of cellular permeability.

Authors:  Michael G Katz; Anthony S Fargnoli; Charles R Bridges
Journal:  Hum Gene Ther       Date:  2013-04-01       Impact factor: 5.695

5.  A needleless liquid jet injection delivery method for cardiac gene therapy: a comparative evaluation versus standard routes of delivery reveals enhanced therapeutic retention and cardiac specific gene expression.

Authors:  A S Fargnoli; M G Katz; R D Williams; K B Margulies; Charles R Bridges
Journal:  J Cardiovasc Transl Res       Date:  2014-10-15       Impact factor: 4.132

6.  In vivo gene gun-mediated transduction into rat heart with Epstein-Barr virus-based episomal vectors.

Authors:  K Nishizaki; O Mazda; Y Dohi; T Kawata; K Mizuguchi; S Kitamura; S Taniguchi
Journal:  Ann Thorac Surg       Date:  2000-10       Impact factor: 4.330

7.  Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.

Authors:  Clemens von Birgelen; Hanim Sen; Ming Kai Lam; Peter W Danse; Gillian A J Jessurun; Raymond W M Hautvast; Gert K van Houwelingen; Alexander R Schramm; R Melvyn Tjon Joe Gin; Johannes W Louwerenburg; Frits H A F de Man; Martin G Stoel; Marije M Löwik; Gerard C M Linssen; Salah A M Saïd; Mark B Nienhuis; Patrick M J Verhorst; Mounir W Z Basalus; Carine J M Doggen; Kenneth Tandjung
Journal:  Lancet       Date:  2013-10-31       Impact factor: 79.321

8.  Therapeutic cell engineering with surface-conjugated synthetic nanoparticles.

Authors:  Matthias T Stephan; James J Moon; Soong Ho Um; Anna Bershteyn; Darrell J Irvine
Journal:  Nat Med       Date:  2010-08-15       Impact factor: 53.440

9.  Anti-inflammatory loaded poly-lactic glycolic acid nanoparticle formulations to enhance myocardial gene transfer: an in-vitro assessment of a drug/gene combination therapeutic approach for direct injection.

Authors:  Anthony S Fargnoli; Anbin Mu; Michael G Katz; Richard D Williams; Kenneth B Margulies; David B Weiner; Shu Yang; Charles R Bridges
Journal:  J Transl Med       Date:  2014-06-16       Impact factor: 5.531
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.